Brimonidine

Alphagan P 0.1%/ 0.15% and the selected generic 0.2% lower elevated IOP in open-angle glaucoma or ocular hypertension. The 0.2% label notes reduced effect over time in some patients and calls for monitoring. These are not universal treatments for every red or painful eye.

Lumify multidose and preservative-free 0.025% relieve redness due to minor eye irritation. Their self-use directions apply from age 5, with doctor consultation below 5. Pain, visual changes or persistent redness require assessment; these products do not provide a glaucoma-management regimen.

Mirvaso gel treats persistent nontransient facial erythema of rosacea in adults 18 or older. It is not for oral, ophthalmic or intravaginal use. Brimonidine / timolol or brinzolamide / brimonidine combinations have separate dosing and contraindications; other formulations and procedures such as post-laser application are outside this reviewed scope.

Remove lenses before Lumify and wait at least 10 minutes before reinsertion; separate other eye products by at least 5 minutes. Selected 0.2% glaucoma drops contain benzalkonium chloride and direct at least 15 minutes before inserting soft lenses. Alphagan P uses a different preservative and its selected label gives no numerical lens-wait direction; follow the actual product / eye clinician rather than automatically transfer the 0.2% rule. Keep tips clean, replace bottle caps and discard used PF vials.

Apply a pea-sized amount once daily to each of five areas: central forehead, chin, nose and each cheek. Spread smoothly as a thin layer across the face, avoiding eyes / lips and irritated skin or open wounds; wash hands afterward. Each gram contains 5 mg brimonidine tartrate equivalent to 3.3 mg free base; 0.33% refers to base. Do not use more frequently or apply an eye-drop dose to skin.

The selected 0.2% label has not studied renal / hepatic impairment and says dialysis effects are unknown. Other selected labels provide no verified numerical renal / hepatic adjustment table. Review systemic vascular risk, concomitant drugs and response; do not invent dose reductions based on topical concentration or a universal missed-dose doubling instruction.

Selected prescription glaucoma drops: age below 2 and previous component hypersensitivity. Mirvaso: component hypersensitivity. Lumify Drug Facts has do-not-use directions for cloudy / discolored solution and, for PF, damaged vial; below 5 needs doctor consultation. The pediatric glaucoma contraindication is not a universal age rule for every product, but no product should be selected without its exact age / route guidance.

The selected glaucoma, OTC and facial brimonidine labels have no boxed warning. Pediatric toxicity, accidental ingestion, cardiovascular effects and local reactions still require active prevention.

Glaucoma drops report ocular allergy / redness / itching, burning / stinging, dry mouth, fatigue / drowsiness, headache and visual disturbance. Mirvaso reports erythema, flushing, burning, contact dermatitis and serious systemic / allergic reactions. OTC Drug Facts specifies warning symptoms rather than a trial-rate comparison. Do not compare percentages from different strengths, indications or populations as one overall risk.

Prescription glaucoma and Mirvaso labels advise caution with antihypertensives / cardiac glycosides because BP may fall. Alcohol, opioids, sedatives, anesthetics and other CNS depressants may add to impairment; dedicated interaction studies are limited. Review symptoms and treatment rather than use a universal dose-change formula.

Prescription glaucoma labels advise caution with tricyclic antidepressants; their known effect on systemic clonidine does not prove a definite brimonidine IOP interaction. MAO inhibitors may theoretically interfere with brimonidine metabolism and increase systemic effects such as hypotension; current selected glaucoma and Mirvaso labels advise caution rather than list MAOI use as a formal contraindication.

Keep at least 5 minutes between selected glaucoma / Lumify and other eye products. Check all active ingredients to avoid duplicate brimonidine or an unreviewed combination product. OTC labels do not supply the full interaction evidence of prescription forms; do not claim that 0.025% is universally interaction-free.

Human pregnancy evidence is insufficient; prescription glaucoma and Mirvaso labels use maternal-benefit / fetal-risk assessment, while Lumify advises a health professional before use. Human milk transfer is unknown. Current Alphagan P does not recommend use during lactation because CNS depression / apnea could occur in infants. Selected older 0.2% and Mirvaso labels call for a nursing-versus-drug decision based on maternal importance; do not treat those as identical instructions or a proof of safety.

Glaucoma drops are contraindicated below 2 and require caution in older children because of somnolence / decreased alertness. Lumify self-use directions start at 5; below 5 consult a doctor. Mirvaso is labeled for adults 18 or older and pediatric effectiveness is unestablished; child ingestion has required hospitalization. Selected Rx trials found no overall age-related difference in older adults, but individual cardiovascular / sedation risk still matters.

Selected 0.2% glaucoma pharmacokinetics have not been studied with renal / hepatic impairment; dialysis effects are unknown. No selected product supplies a fixed organ-adjustment schedule. Depression, vascular insufficiency or severe cardiovascular disease requires caution with prescription drops / gel; use the actual clinical risk and labeled route rather than infer safety from low plasma exposure.

Glaucoma brimonidine reduces aqueous-humor production and increases uveoscleral outflow, lowering IOP. Mirvaso may reduce facial erythema by direct vasoconstriction. OTC Lumify’s labeled role is minor-irritation redness relief; it does not establish an approved glaucoma regimen.

Glaucoma labels describe measurable systemic exposure: Alphagan P summarizes ocular-study peaks 0.5–2.5 hours and half-life about 2 hours; selected 0.2% reports peaks 1–4 hours and half-life about 3 hours. Brimonidine is metabolized by the liver and drug / metabolites eliminated mainly in urine. Mirvaso facial-use studies measured low pg / mL plasma levels, but systemic adverse effects have occurred. None of these observations establishes a universal half-life, renal dose or safe ingestion amount.

For glaucoma follow IOP, ocular condition and tolerability, including allergy, fatigue and loss of effect over time. Review cardiovascular / vascular disease and sedating / BP medicines. For Mirvaso assess response, rebound redness, local allergy and dizziness / bradycardia / hypotension symptoms. Lumify warning triggers include pain, visual changes or persistence beyond 3 days; no universal IOP target, follow-up interval or blood-drug test is specified.

Verify product name, concentration, route and age. Follow bottle / PF handling, contact-lens waits and 5 minute eye-product spacing; do not touch tips to surfaces. Mirvaso is once-daily facial use only, avoiding lips / eyes / open skin; wash hands and retain child-resistant closure. Drowsiness can impair driving. Report severe allergy, worsening skin redness or concerning systemic symptoms promptly.

Seek immediate medical / Poison Control help for swallowed drops / gel, child exposure or significant overdose; profound lethargy, slow pulse or breathing difficulty is an emergency. Prescription labels describe supportive treatment and airway protection, not a home antidote. Do not inject products, put facial gel into eyes or guess a replacement dose after uncertain use.

Product

Alphagan P 0.1% brimonidine tartrate solution

Route

Topical ophthalmic; prescription

Appearance

Sterile solution in teal opaque bottle; purple cap

Example package

5 mL · NDC 0023-9321-05

Alphagan P: 0.1% and 0.15% tartrate (1 and 1.5 mg / mL) with PURITE. Selected generic: 0.2% tartrate (2 mg / mL), greenish-yellow solution with benzalkonium chloride; 5 mL NDC 24208-411-05. Lumify forms: 0.025% tartrate (0.25 mg / mL), multidose bottle or preservative-free 0.4 mL single-use vials. Mirvaso: 0.33% free-base gel, equivalent to 5 mg tartrate / g; 30 g tube NDC 0299-5980-30. Other combinations / formulations need separate review.

Selected Alphagan P and 0.2% glaucoma drops: 15–25°C; keep capped, do not use cloudy / discolored solution or past expiry. Lumify bottle / PF: 15–25°C; PF requires intact vial / sealed pouch, protection from light, unused vials in child-resistant carton and immediate discard after use. Mirvaso: 20–25°C, excursions 15–30°C, child-resistant tube / pump closure. No universal 28 day opened-bottle discard is supplied in these labels.